NAS:WGS (USA)
Â
Ordinary Shares - Class A
$
100.59
-2.6 (-2.52%)
12:08 AM EST
What is a stock summary page? Click here for an overview.
Business Description
GeneDx Holdings Corp
NAICS : 621511
SIC : 8734
ISIN : US81663L1017
Share Class Description:
WGS: Ordinary Shares - Class ADescription
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.22 | |||||
| Equity-to-Asset | 0.59 | |||||
| Debt-to-Equity | 0.47 | |||||
| Debt-to-EBITDA | -4.61 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 6 | |||||
| Beneish M-Score | -2.29 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -44 | |||||
| 3-Year EBITDA Growth Rate | 91.1 | |||||
| 3-Year EPS without NRI Growth Rate | 78 | |||||
| 3-Year FCF Growth Rate | 73 | |||||
| 3-Year Book Growth Rate | -45.1 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 15.41 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 56.59 | |||||
| 9-Day RSI | 55.83 | |||||
| 14-Day RSI | 55.5 | |||||
| 3-1 Month Momentum % | 23.84 | |||||
| 6-1 Month Momentum % | 160.18 | |||||
| 12-1 Month Momentum % | 1030.31 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.61 | |||||
| Quick Ratio | 3.42 | |||||
| Cash Ratio | 2.58 | |||||
| Days Inventory | 34.27 | |||||
| Days Sales Outstanding | 38.64 | |||||
| Days Payable | 29.47 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -56.2 | |||||
| Shareholder Yield % | -2.73 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 63.64 | |||||
| Operating Margin % | -7.6 | |||||
| Net Margin % | -17.12 | |||||
| FCF Margin % | -11.13 | |||||
| ROE % | -24.23 | |||||
| ROA % | -12.87 | |||||
| ROIC % | -8.56 | |||||
| 3-Year ROIIC % | 258.58 | |||||
| ROC (Joel Greenblatt) % | -79.41 | |||||
| ROCE % | -13.71 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 105.88 | |||||
| PS Ratio | 8.88 | |||||
| PB Ratio | 11.5 | |||||
| Price-to-Tangible-Book | 32.55 | |||||
| EV-to-EBIT | -60.88 | |||||
| EV-to-EBITDA | -113.88 | |||||
| EV-to-Revenue | 9.4 | |||||
| EV-to-FCF | -84.48 | |||||
| Price-to-GF-Value | 6.97 | |||||
| Price-to-Net-Current-Asset-Value | 118.34 | |||||
| Earnings Yield (Greenblatt) % | -1.64 | |||||
| FCF Yield % | -1.2 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:WGS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
GeneDx Holdings Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 305.45 | ||
| EPS (TTM) ($) | -1.96 | ||
| Beta | 2.2 | ||
| 3-Year Sharpe Ratio | 0.56 | ||
| 3-Year Sortino Ratio | 1.08 | ||
| Volatility % | 114.34 | ||
| 14-Day RSI | 55.5 | ||
| 14-Day ATR ($) | 8.330984 | ||
| 20-Day SMA ($) | 97.0595 | ||
| 12-1 Month Momentum % | 1030.31 | ||
| 52-Week Range ($) | 8.295 - 115.5999 | ||
| Shares Outstanding (Mil) | 28.07 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
GeneDx Holdings Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
GeneDx Holdings Corp Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
GeneDx Holdings Corp Frequently Asked Questions
What is GeneDx Holdings Corp(WGS)'s stock price today?
The current price of WGS is $100.59. The 52 week high of WGS is $115.60 and 52 week low is $8.30.
When is next earnings date of GeneDx Holdings Corp(WGS)?
The next earnings date of GeneDx Holdings Corp(WGS) is 2025-04-29 Est..
Does GeneDx Holdings Corp(WGS) pay dividends? If so, how much?
GeneDx Holdings Corp(WGS) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers